Focusing on Clinical Development
Seattle Genetics is a clinical-stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In December 2009, we entered into an agreement with Millennium: The Takeda Oncology Company under which Seattle Genetics retains full commercialization rights to brentuximab vedotin in the United States and Canada, while Millennium obtained rights to commercialize the product candidate in all other countries.

In addition to brentuximab vedotin, Seattle Genetics has five other clinical-stage product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-75, and ASG-5ME for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers monoclonal antibodies targeted to tumor cells by stably linking them to potent anti-cancer agents. Our novel linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity. Our clinical-stage ADCs include brentuximab vedotin, SGN-75 and ASG-5ME, and we are advancing several preclinical ADC product candidates, including SGN-19A.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our collaboration agreement with Millennium: The Takeda Oncology Company to globally develop and commercialize brentuximab vedotin, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $120 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.